The O
levels O
of O
5,6-EET B-lipid
cannot O
be O
accurately O
estimated O
because O
of O
its O
lability. O

Similar O
to O
PI, O
PG36:5, B-lipid
PG38:8, B-lipid
PG38:3, B-lipid
PG40:6 B-lipid
and O
PG40:3 B-lipid
were O
detected O
by O
all O
protocols, O
but O
with O
a O
gradual O
increase O
in O
their O
intensities O
from O
protocols O
(i) O
to O
(vi). O

Circulating O
PC O
species, O
containing O
linoleic O
acids O
(PC O
34:2, O
PC B-lipid
36:2, I-lipid
PC B-lipid
38:2) I-lipid
and O
α-linolenic O
acids O
(PC O
34:3, O
PC B-lipid
36:3, I-lipid
PC B-lipid
38:3), I-lipid
were O
markedly O
increased O
in O
these O
patients, O
whereas O
those O
containing O
arachidonic O
acid O
remained O
unaffected O
(D–G). O

Significant O
amounts O
of O
cholesterol O
and O
TG(17:2/17:2/18:0) B-lipid
were O
detected O
following O
MTBE O
extraction, O
and O
these O
could O
not O
be O
detected O
when O
methanol O
alone O
was O
used. O

ATP O
adenosine O
triphosphate, O
Fatty O
acids O
capric O
acid, O
cis-9-palmitoleic O
acid, O
dodecanoic B-lipid
acid, I-lipid
oleic O
acid, O
palmitic O
acid O
or O
stearic O
acid, O
MDD O
major O
depressive O
disorder, O
PUFAs O
eicosapentaenoic B-lipid
acid I-lipid
(EPA, O
ω-3) O
and O
arachidonic O
acid O
(AA, O
ω-6), O
SAM O
S-adenosylmethionine, O

(A) O
Insulin; O
(B) O
Glucose; O
(C) O
Alanine O
transaminase O
(ALT); O
(D) O
Aspartate O
transaminase O
(AST); O
(E) O
Triacylglycerides O
(TAG); O
(F) O
Cholesterol; B-lipid
(D) O
Low-density O
lipoprotein O
cholesterol O
(LDL-C); O
(H) O
High-density O
lipoprotein O
cholesterol O
(HDL-C). O

5-, O
12- O
and O
15-hydroxyeicosatetraenoic B-lipid
acid I-lipid
(5-HETE, O
12-HETE, B-lipid
15-HETE), O
prostaglandin O
E_2 O
, O
D_2 O
and O
F_2 O
(PGE_2 O
, O
PGD_2 O
, O
PGF_2 O
), O
lipoxin O
A_4 O
and O
B_4 O
(LXA_4 O
, O
LXB_4 O
), O
leukotriene O
B_4 O
(LTB_4 O
), O
thromboxane O
B_2 O
(TXB_2 O
), O
arachidonic O
acid O
(AA), O
docosahexaenoic B-lipid
acid I-lipid
(DHA), O
eicosapentanoic O
acid O
(EPA), O
resolvin O
D1 O
(RvD1), O
and O
neuroprotectin O
D1 O
(NPD1). O

Compared O
with O
the O
AUC_ROC O
value O
of O
the O
base O
model O
of O
BMI, O
history O
of O
hypertension, O
smoking, O
physical O
activity, O
triglycerides, O
and O
HDL O
cholesterol, O
no O
metabolites O
led O
to O
a O
significant O
increase O
in O
AUC O
values, O
whereas O
IDI O
and O
NRI O
statistics O
showed O
that O
dihomo-γ O
-linolenic O
acid O
and O
LPI B-lipid
(16:1) I-lipid
could O
significantly O
improve O
risk O
reclassification O
of O
incident O
type O
2 O
diabetes O
at O
P O
< O
0.01. O

Thirdly, O
classification O
using O
ROC O
analysis O
identified O
pentadecanoic B-lipid
acid, I-lipid
linoleoyl O
carnitine O
and O
1-linoleoylglycerophosphocholine O
as O
the O
top O
discriminating O
metabolites O
in O
determining O
the O
extent O
of O
myocardial O
injury. O

In O
agreement O
with O
us, O
some O
authors O
have O
already O
shown O
in O
humans O
that O
20-HETE B-lipid
was O
associated O
with O
hypertension O
and O
BMI O

The O
levels O
of O
PE(18:0/18:2) B-lipid
and O
PC(15:0/18:1) B-lipid
in O
early-stage O
NSCLC O
were O
significantly O
increased O
compared O
with O
LBD O
(p<0.05). O

Filled O
circles O
illustrate O
retention O
time O
of O
the O
authentic O
standards, O
PC(18:1/18:1), B-lipid
PC(18:0/20:4) B-lipid
and O
PC(18:0/22:6), B-lipid
confirming O
the O
predicted O
pattern. O

We O
selected O
21 O
metabolites O
because O
two O
metabolites, O
LysoPC(16:0) B-lipid
and O
7-dehydrocholesterol-1, O
overlapped O
in O
both O
diseases, O
and O
investigated O
the O
accuracy O
of O
differential O
diagnosis O
between O
the O
two O
parkinsonian O
disorders. O

In O
addition, O
concentrations O
of O
nonanoic B-lipid
acid I-lipid
and O
perillic O
acid O
were O
correlated O
with O
the O
PANSS O
general O
psychopathology O
subscore O
(ρ O
=0.671, O
P O
=0.024 O
and O
ρ O
=0.639, O
P O
=0.034, O
respectively). O

Docosahexaenoic B-lipid
acid I-lipid
is O
an O
important O
structural O
component O
of O
the O
human O
brain, O
cerebral O
cortex, O
and O
the O
discs O
of O
the O
rod O
photoreceptor O
cells. O

The O
overweight O
group O
showed O
significant O
decreases O
in O
11 O
metabolites—lysoPCs O
containing O
C14:0, O
C16:1, O
C16:0, O
C17:0, O
C18:2, O
C18:1, O
C18:0, O
C20:4, O
C20:3, O
and O
C22:6 O
(Suppl. O
1), O
and O
PC O
(18:0/20:4)—and O
significant O
increases O
in O
6 O
metabolites—L-leucine, O
palmitic O
amide, O
L-octanoylcarnitine, O
decanoylcarnitine, O
PC B-lipid
(18:2/18:2), I-lipid
and O
lactosylceramide. O

As O
shown O
in O
, O
linoleic O
acid O
and O
12,13-DiHOME B-lipid
were O
significantly O
elevated O
at O
high O
altitude. O

Lower O
muscle O
lipids O
in O
OIR O
versus O
Lean O
included O
GM3(d18:1/22:0), B-lipid
LPC(22:6), B-lipid
LPE(22:6), B-lipid
and O
DG(18:2_18:2). B-lipid

An O
example O
of O
this O
involves O
the O
conversion O
of O
20-HETE B-lipid
to O
ω-hydroxy O
arachidonic O
acid, O
and O
the O
subsequent O
conversion O
to O
20-carboxy O
arachidonic O
acid O
(DCA O
20:4) O
by O
alcohol O
dehydrogenase O
and O
fatty O
aldehyde O
dehydrogenase. O

Pro-inflammatory O
mediators O
PGF_2α O
and O
PGF_3α O
and O
oxidative O
stress O
markers O
iPF_2α O
- O
IV, O
11-HETE B-lipid
and O
14-HDoHE B-lipid
were O
positively O
associated O
with O
improvement O
of O
disease O
activity O
score. O

Until O
recently O
it O
was O
assumed O
that O
the O
existence O
of O
straight O
chain O
odd O
number O
fatty O
acids O
such O
as O
pentadecanoic B-lipid
acid I-lipid
(15:0) O
in O
normal O
physiological O
conditions O
were O
rare. O

Notably, O
decreased O
plasma O
concentrations O
of O
LPC18:1 B-lipid
and O
LPC18:2 B-lipid
have O
been O
detected O
in O
both O
subjects O
with O
metabolically O
unhealthy O
obesity O
and O
metabolically O
healthy O
obesity. O

The O
intensities O
and O
compositions O
of O
18 O
FFAs O
were O
also O
identified, O
and O
the O
intensities O
of O
FA B-lipid
16:2, I-lipid
18:3, O
18:4, O
and O
C22:5 O
were O
significantly O
lower O
in O
the O
recurrent O
AF O
group. O

Moreover, O
high O
levels O
of O
Lp-PLA2 O
and O
LysoPC(16:0) B-lipid
are O
associated O
with O
symptomatic O
carotid O
plaques. O

The O
levels O
of O
PE(16:0/16:1), B-lipid
PE(16:0/18:3), B-lipid
PE(16:0/18:2), B-lipid
PE(18:0/16:0), B-lipid
PE(17:0/18:2), B-lipid
PE(18:0/17:1), B-lipid
PE(17:0/18:1), B-lipid
PE(20:5/16:0), B-lipid
PE(18:0/18:1), B-lipid
PE(18:1/20:4), B-lipid
PE(18:0/20:3), B-lipid
PC(15:0/18:1), B-lipid
PC(16:1/20:5), B-lipid
and O
PC(18:0/20:1) B-lipid
in O
early-stage O
NSCLC O
were O
significantly O
increased O
compared O
with O
HC O
(p<0.05). O

Filled O
circles O
illustrate O
retention O
time O
of O
the O
authentic O
standards, O
PC(18:1/18:1), B-lipid
PC(18:0/20:4) B-lipid
and O
PC(18:0/22:6), B-lipid
confirming O
the O
predicted O
pattern. O

SM O
and O
Cholesterol B-lipid
(d7). O

That O
is, O
the O
lipids O
are O
identified O
by O
their O
total O
acyl/alkyl O
chain O
content O
(i.e. O
PC(38:4)) B-lipid
as O
opposed O
to O
their O
precise O
chemical O
structure. O

Each O
sample O
was O
added O
with O
the O
internal O
standards, O
PC(17:0/0:0), B-lipid
PC(17:0/17:0), B-lipid
PE B-lipid
(17:0/17:0), I-lipid
PG(17:0/17:0), B-lipid
Cer(d18:1/17:0), B-lipid
PS(17:0/17:0), B-lipid
PA(17:0/17:0), B-lipid
racemic O
MG(17:0/0:0/0:0), B-lipid
racemic O
DG(17:0/17:0/0:0) B-lipid
and O
TG(17:0/17:0/17:0) B-lipid
. O

Three O
metabolites O
were O
identified O
that O
contributed O
to O
the O
group O
separation O
in O
both O
studies: O
3,4-dihydroxybutanoic B-lipid
acid, I-lipid
docosapentaenoic B-lipid
acid, I-lipid
and O
uric O
acid. O

This O
class O
ionize O
highly O
efficiently O
in O
positive O
mode O
but O
the O
corresponding O
MS2 O
spectra O
by O
higher-energy O
collisional O
dissociation O
(HCD) O
only O
delivers O
head O
group-specific O
fragments O
that O
cannot O
help O
to O
identify O
the O
fatty O
acyl O
chain O
composition O
(compare O
lipid O
species O
level O
(e.g., O
PC B-lipid
32:1) I-lipid
and O
molecular O
species O
level O
(e.g., O
PC O
16:0_16:1)). O

These O
two O
diabetes O
risk O
assessments O
were O
also O
inversely O
correlated O
to O
several O
fatty O
acids, O
including O
lauric O
acid, O
linoleic O
acid, O
palmitoleic O
acid O
and O
oleic O
acid, O
as O
well O
aminomalonate O
and O
3-hydroxybutanoic B-lipid
acid. I-lipid

In O
our O
case, O
the O
levels O
of O
PC(20:4/0:0), B-lipid
PC(22:6/0:0), B-lipid
were O
increased O
in O
the O
serum O
of O
rapid O
fibrosers O
when O
compared O
with O
slow O
fibrosers; O
in O
contrast, O
the O
levels O
of O
PC(18:2/20:4), B-lipid
and O
PC(40:8) B-lipid
decreased. O

In O
the O
esterified O
PUFA O
categories, O
there O
was O
significant O
postprandial O
reduction O
in O
abundance O
of O
several O
n-3 O
PUFAs, O
particularly O
docosahexaenoic B-lipid
acid I-lipid
(DHA), O
docosapentaenoic B-lipid
acid I-lipid
(DPA), O
and O
eicosapentaenoic B-lipid
acid I-lipid
(EPA), O
and O
in O
n-6 O
PUFA, O
dihomo-γ-linolenic O
acid O
(DGLA). O

The O
metabolomic O
study O
above O
had O
indicated O
that O
LPC(14:0) B-lipid
was O
downregulated O
in O
HCC O
versus O
LC O
and O
the O
profiling O
study O
confirmed O
this O
and O
also O
showed O
that O
this O
LPC O
was O
downregulated O
in O
HCC O
versus O
HV. O

Interestingly, O
PC(32:0), B-lipid
which O
could O
correspond O
to O
PC(16:0/16:0), B-lipid
was O
recently O
reported O
as O
a O
potential O
signature O
of O
progressive O
forms O
of O
fatty O
liver O
disease. O

Box-whisker O
plots O
of O
the O
concentrations O
of O
(A) O
4-heptanone, O
(B) O
2-methylpyrazine, O
(C) O
2-methylbutanal, B-lipid
(D) O
2,6-dimethyl-7-octen-2-ol O
and O
(E) O
decanoic B-lipid
acid. I-lipid

6d, O
JWH-210 O
5-hydroxyindole; O
6e, O
JWH-210 O
pentanoic B-lipid
acid; I-lipid
7a, O
JWH-250; O
7b, O
JWH-250 O
5-hydroxypentyl; O
7c, O
JWH-250 O
4-hydroxypentyl; O
7d, O
JWH-250 O
5-hydroxyindole; O
7e, O
JWH-250 O
pentanoic B-lipid
acid; I-lipid
8a, O
RCS-4; O
8b, O
RCS-4 O
5-hydroxypentyl; O
8c, O
RCS-4 O
pentanoic B-lipid
acid; I-lipid
9a, O
AM2201; O
9b, O
AM2201 O
4-hydroxypentyl; O
9c, O
AM2201 O
6-ydroxyindole; O
10a, O
MAM2201. O

520.36 O
Da] O
and O
LPC(18:1) B-lipid

The O
receiver O
operating O
characteristic O
(ROC) O
analysis O
of O
23 O
phospholipid O
species O
(Table _S2 O
) O
found O
that O
9 O
phospholipid O
species O
including O
PC B-lipid
(18:1/16:0), I-lipid
PC B-lipid
(16:0/18:2), I-lipid
PC B-lipid
(16:0/16:0), I-lipid
PC B-lipid
(16:1/16:0), I-lipid
PC B-lipid
(16:0/14:0), I-lipid
PE B-lipid
(22:6/18:1), I-lipid
PE B-lipid
(16:0/20:4), I-lipid
PE B-lipid
(18:2/20:4), I-lipid
LPA B-lipid
(16:0) I-lipid
had O
greater O
diagnostic O
power O
with O
an O
area O
under O
the O
ROC O
(AUC) O
greater O
than O
0.7, O
and O
the O
predictive O
power O
of O
PC O
were O
greater O
than O
PE O
and O
LPA O
(Table ). O

Metabolites O
such O
as O
valine, O
sarcosine, O
hexanedioic B-lipid
acid, I-lipid
and O
cholesterol O
could O
be O
possibly O
potential O
biomarkers O
and O
need O
to O
be O
validated. O

ABCD2 O
+ O
LAA O
+ O
LysoPC(20:4) B-lipid
= O
0.711, O
p O
< O
0.001; O
integrated O
discrimination O
improvement O
(IDI) O
test O
for O
comparison O
of O
prediction O
models: O
p O
< O
0.0001). O

The O
models O
identified O
important O
biomarkers: O
lauric O
acid O
(C12:0), O
myristic O
acid O
(C14:0), O
stearic O
acid O
(C18:0), O
lignoceric O
acid O
(C24:0), O
palmitic O
acid O
(C16:0) O
and O
heptadecanoic B-lipid
acid I-lipid
(C17:0) O
among O
saturated O
fatty O
acids, O
Cis-10-pentadecanoic O
acid O
(C15:1), O
Cis-11-eicosenoic O
acid O
(C20:1n9), O
and O
erucic O
acid O
(C22:1n9) O
among O
monounsaturated O
fatty O
acids O
and O
the O
Gamma-linolenic O
acid O
(C18:3n6) O
polyunsaturated O
fatty O
acid. O

For O
co-eluting O
isobars O
a O
unique O
fragment O
ion O
was O
chosen, O
as O
for O
12-HETE B-lipid
(m O
/z O
319 O
→ O
179) O
and O
8-HETE B-lipid
(m O
/z O
319 O
→ O
115), O
both O
eluting O
at O
t O
_R O
19.24 O
(Fig. ). O

These O
two O
metabolites O
induce O
chemotactic O
response O
and O
chemokinesis O
of O
leukocytes O
and O
show O
increased O
levels O
in O
inflammatory O
lesions O
for O
immune O
function, O
therefore, O
5-HETE B-lipid
and O
leukotriene O
B_4 O
may O
play O
a O
key O
role O
on O
leukocyte O
function. O

Relative O
to O
the O
control, O
the O
major O
sn O
-isomer O
PC B-lipid
16:0/18:1 I-lipid
and O
the O
CC O
location O
isomer O
C18:1(Δ9) O
were O
found O
to O
increase O
significantly O
in O
the O
cancerous O
tissue O
samples O
(P O
= O
3.5 O
× O
10_–7 O
and O
P O
= O
2 O
× O
10_–4 O
, O
respectively, O
). O

In O
addition O
a O
decrease O
in O
TAG(52:1) B-lipid
was O
detected. O

In O
addition, O
the O
concentrations O
of O
the O
3 O
volatile O
metabolites O
(4-heptanone, O
2-methylbutanal B-lipid
and O
decanoic O
acid) O
were O
significantly O
different O
between O
aggressive O
B-NHL O
and O
indolent O
B-NHL. O

A O
recent O
lipidomics O
study O
of O
human O
acquired O
obesity O
found O
increased O
adipose O
tissue O
levels O
of O
eicosapentaenoic B-lipid
acid, I-lipid
a O
precursor O
of O
anti-inflammatory O
related O
docosahexaenoic B-lipid
acid I-lipid
(DHA). O

The O
levels O
of O
PA, O
D-Maltose, O
and O
PG B-lipid
(12:0/13:0) I-lipid
were O
highest O
in O
BT O
group, O
followed O
by O
PP O
group, O
and O
finally O
GP O
group. O

Cholesterol B-lipid
is O
metabolized O
via O
different O
processes O
into O
2 O
major O
primary O
bile O
acids O
(CDCA O
and O
CA). O

The O
100 O
μL O
urine O
sample O
were O
added O
into O
centrifuge O
tube O
and O
15 O
μL O
10 O
mg/mL O
urease O
solution O
were O
added; O
vortex O
mixing O
for O
10 O
s O
and O
treated O
with O
37°C O
water O
bath O
for O
1 O
h; O
1000 O
μL O
tridecanoic B-lipid
acid I-lipid
internal O
standard O
solution O
was O
added O
and O
high O
speed O
vortex O
for O
5 O
min O
at O
room O
temperature; O
and O
then O
centrifuged O
for O
15 O
min O
at O
4°C, O
15000 O
rpm; O
1000 O
μL O
supernatant O
was O
transferred O
into O
a O
centrifuge O
tube, O
drying O
at O
room O
temperature O
with O
nitrogen; O
adding O
100 O
μL O
Pyridine O
pyridine O
solution O
(15 O
mg/mL) O
into O
the O
dried O
sample O
and O
investigating O
the O
diffient O
temperature O
and O
time; O
adding O
10 O
μL O
derivatization O
reagents O
(MSTFA: O
TMCS=100:1 O
v/v) O
and O
nvestigating O
the O
different O
temperature O
and O
time; O
centrifuing O
at O
3000 O
rpm O
for O
10 O
min O
at O
room O
temperature O
and O
transferring O
supernatant O
to O
dry O
clean O
centrifuge O
tube O
and O
to O
be O
GC-MS O
analysis. O

Similarly, O
fatty O
acids O
levels O
increased O
significantly, O
including O
2,4-dihydroxybutyric O
acid, O
2-hydroxy-3-methylbutyric O
acid, O
3,4-dihydrxoybutyric O
acid, O
6-aminocaproic O
acid, O
pentanoic B-lipid
acid, I-lipid
and O
glyceraldehyde, O
whereas O
the O
bile O
acid O
glycochenodeoxycholate-3-sulfate O
(GCDCA-3-sulfate) O
decreased. O

95% O
CI O
of O
0.95−0.98), O
the-CH O
group O
(δ O
2.61, O
r O
= O
0.88; O
95% O
CI O
of O
0.85−0.91), O
and O
the O
methyl O
group O
from O
the O
propionic B-lipid
acid I-lipid
side O
chain O
(δ O
1.07, O
r O
) O
0.87; O
95% O
CI O
of O
0.92–0.9). O

In O
the O
present O
study, O
we O
observed O
significantly O
decreased O
concentrations O
of O
unsaturated O
LPC, O
LPC18:2, B-lipid
LPC18:1, B-lipid
LPC20:2, B-lipid
LPC20:1, B-lipid
and O
LPC20:0 B-lipid
in O
obese O
adolescents, O
which O
were O
not O
affected O
by O
traditional O
clinical O
plasma O
lipid O
levels. O

In O
addition, O
lower O
total O
LPC, O
LPC18:0, B-lipid
LPC18:2, B-lipid
and O
LPC20:4 B-lipid
levels O
were O
measured O
in O
obese O
and O
obese O
subjects O
with O
type O
2 O
diabetes O
than O
in O
nonobese O
adults. O

(d17So1P), O
Ceramide B-lipid
(d18:1/17:0) I-lipid
(C17Cer), O
and O
glucosylceramide O
(d18:1/17:0) O
(C17GlcCer) O
were O
purchased O
from O
Avanti O
Polar O
Lipids. O

These O
included O
both O
enzymatic O
(15- O
and O
12-hydroxyeicosatetraenoic B-lipid
acid, I-lipid
pro-inflammatory O
lipoxygenase O
products) O
and O
nonenzymatic O
(5-, O
9-, O
and O
11-hydroxyeicosatetraenoic O
acid) O
oxidation O
products O
of O
arachidonic O
acid. O

The O
assay O
exhibited O
a O
linear O
dynamic O
range O
of O
0.02–4 O
and O
0.08–16 O
μg/ml O
for O
Cer(22:0) B-lipid
and O
Cer(24:0), B-lipid
respectively, O
in O
human O
plasma O
with O
corresponding O
absolute O
recoveries O
from O
plasma O
at O
109 O
and O
114%, O
respectively. O

For O
instance, O
PC B-lipid
16:0_17:0 I-lipid
was O
found O
to O
exhibit O
significant O
changes O
in O
sn O
-ratios O

In O
the O
present O
study, O
the O
concentration O
levels O
of O
3 O
volatile O
metabolites O
(4-heptanone, O
2-methylpyrazine O
and O
2-methylbutanal) B-lipid
in O
urine O
samples O
from O
patients O
with O
B-NHL O
were O
significantly O
higher O
compared O
with O
non-lymphoma O
subjects, O
and O
the O
concentration O
of O
1 O
of O
the O
metabolites O
(4-heptanone) O
was O
significantly O
different O
between O
early O
and O
advanced O
stages O
of O
lymphoma, O
indicating O
that O
4-heptanone O
may O
be O
a O
potentially O
useful O
biomarker O
for O
screening O
of O
B-NHL. O

3-hydroxybutanoic B-lipid
acid I-lipid
(β-hydroxybutyrate; O
BHBA) O
is O
an O
organic O
acid, O
which O
is O
used O
for O
the O
biosynthesis O
of O
fatty O
acids. O

Lysophosphatidylcholines O
(LysoPCs) O
including O
LysoPC(18:2), B-lipid
LysoPC(20:3) B-lipid
and O
LysoPC(22:5) B-lipid
were O
obviously O
decreased O
in O
plasma O
from O
HAPE O
subjects O
relative O
to O
healthy O
controls, O
suggesting O
the O
phospholipid O
metabolism O
is O
implicated O
in O
stroke O
patients. O

After O
vortexing, O
a O
volume O
of O
100 O
μl O
mixture O
was O
transferred O
to O
a O
glass O
vial O
spiked O
with O
internal O
standards O
(10 O
μl O
heptadecanoic B-lipid
acid I-lipid
at O
1 O
mg/ml O
and O
4-chlorophenylalanine O
at O
0.3 O
mg/ml). O

Also O
in O
that O
report, O
the O
authors O
demonstrated O
that O
the O
extractive O
response O
of O
the O
sorbent O
was O
greater O
when O
larger O
sample O
headspace O
volumes O
were O
used, O
at O
least O
for O
the O
model O
metabolites O
isoprene, O
pentane, O
toluene O
and O
pentanal. B-lipid

All O
other O
organic O
acid O
standards O
including O
lactic O
acid, O
beta-hydroxybutyric O
acid, O
alpha-ketoglutaric O
acid, O
citric O
acid, O
butyric O
acid, O
isobutyric O
acid, O
propionic B-lipid
acid, I-lipid
p-hydroxyhippuric O
acid, O
succinic O
acid, O
fumaric O
acid, O
pyruvic O
acid, O
hippuric O
acid, O
methylmalonic O
acid, O
homovanillic O
acid, O
indole-3-acetic O
acid, O
uric O
acid, O
and O
their O
isotope-labeled O
standards O
were O
purchased O
from O
Sigma-Aldrich O
(St. O
Louis, O
MO, O
USA). O

Cholesterol B-lipid
in O
HDL O
particles O
appeared O
most O
unassociated, O
in O
contrast O
to O
previous O
MVPA O
measures O
(current O
and O
longer O
term). O

Similar O
trends O
in O
the O
increase O
of O
relative O
abundance O
of O
PS(40:4), B-lipid
m/z O
838.3 O
with O
increase O
of O
the O
oligodendroglioma O
grade O
are O
observed O
in O
the O
mixed O
oligoastrocytomas, O
likely O
representing O
the O
oligodendrioglial O
character O
of O
this O
mixed O
glioma. O

The O
relative O
ion O
abundance O
of O
the O
sn O
-1 O
fragment O
of O
PC B-lipid
18:1/16:0 I-lipid
(m O
/z O
445) O
was O
normalized O
to O
the O
sum O
of O
sn O
-1 O
fragments O
of O
both O
isomers O
and O
plotted O
against O
corresponding O
concentrations O
(% O
mol). O

Hexanal B-lipid
is O
a O
breakdown O
product O
of O
lipid O
peroxidation O
that O
is O
formed O
as O
a O
result O
of O
oxygen O
free O
radical O
activity. O

As O
a O
result, O
nonanoic B-lipid
acid I-lipid
(C9) O
and O
p-hydroxybenzoic O
acid O
displayed O
relatively O
high O
sensitivity, O
with O
values O
of O
86.7% O
and O
90%, O
respectively. O

LPC(17:0), B-lipid
the O
only O
odd O
chain O
LPC O
detected O
in O
our O
study, O
showed O
different O
behavior O
than O
other O
LPCs, O
with O
non-significant O
correlation O
with O
the O
disease O
and O
negative O
correlation O
to O
the O
parasitaemia O
values. O

(C) O
Tandem O
mass O
spectra O
from O
one O
of O
these O
missing O
entries O
(C_22 O
H_34 O
O_3 O
) O
was O
found O
to O
be O
highly O
similar O
to O
the O
tandem O
mass O
spectra O
for O
10-HDoHE B-lipid
with O
both O
sharing O
common O
fragments O
(blue O
arrows) O
as O
well O
as O
analogous O
fragments O
that O
were O
shifted O
by O
the O
mass O
of O
two O
hydrogens O
(orange O
arrows). O

Response O
change O
of O
glutamate O
and O
PC(16:0/0:0) B-lipid
heated O
at O
different O
temperatures O
and O
durations. O

In O
the O
present O
study, O
PRA O
correlated O
positively O
with O
plasma O
levels O
of O
20-HETE B-lipid
in O
subjects O
with O
RVD. O

The O
three O
most O
abundant O
lipids O
in O
sperm O
were O
sphingomyelin O
(SM) O
16:0, O
PC B-lipid
38:6 I-lipid
and O
PC B-lipid
28:1. I-lipid

Among O
the O
20 O
healthy O
adults, O
18 O
(90%) O
had O
ZS O
scores O
below O
the O
optimal O
cutoff O
of O
−0.1634, O
15 O
(75%) O
had O
PE B-lipid
(18:2) I-lipid
scores O
below O
the O
cutoff O
of O
1447.81, O
14 O
(70%) O
had O
GNOE O
scores O
lower O
than O
the O
cutoff O
of O
227.56, O
and O
17 O
(85%) O
had O
MG B-lipid
(18:2) I-lipid
scores O
less O
than O
the O
cutoff O
of O
237.9. O

Cholesterol, B-lipid
which O
is O
essential O
for O
parasite O
intra-erythrocytic O
growth O
(Bansal O
et O
al. O
) O
and O
infection O
(Samuel O
et O
al. O
), O
is O
also O
fully O
obtained O
from O
the O
host. O

TAG(54:5) B-lipid
therefore O
is O
an O
exception O
of O
a O
decreasing O
serum O
TAG O
with O
more O
than O
52 O
carbons. O

The O
LPCAT1, O
which O
converts O
LPC O
into O
PCs, O
is O
overexpressed O
in O
several O
cancers O
and O
is O
associated O
with O
colon O
cancer O
growth O
(, O
) O
showed O
that O
LPCAT4 O
was O
overexpressed O
in O
CRC O
and O
contributes O
to O
PC B-lipid
(16:0/16:1) I-lipid
accumulation O
via O
the O
enhanced O
re-acylation O
of O
LPC. O

Since O
no O
matrix O
suppression O
was O
observed, O
low O
recoveries O
of O
5,6-EET B-lipid
most O
likely O
resulted O
from O
degradation O
and O
losses O
during O
sample O
preparation, O
which O
were O
compensated O
by O
the O
use O
of O
deuterated O
5,6-EET-d_11 O
as O
indicated O
in O
its O
accuracy O
determination. O

The O
data O
show O
that O
in O
some O
cases O
multiple O
lipid O
species O
are O
present O
in O
a O
single O
nominal O
mass O
peak O
(e.g., O
m/z O
750, O
[PE O
P-36:2 B-lipid
+ O
Na]_+ O
), O
while O
other O
peaks O
are O
principally O
due O
to O
a O
single O
lipid O
species O
(e.g., O
m/z O
754, O
[PC O
32:1 O
+ O
Na]_+ O
). O

The O
extraction O
solvent O
was O
spiked O
with O
compounds O
not O
detected O
in O
unspiked O
human O
stool O
samples O
[SM(d18:1/16:0), O
PE(17:0/17:0), B-lipid
PC(19:0/19:0), B-lipid
TAG(13:0/13:0/13:0), B-lipid
Cer(d18:1/17:0) B-lipid
and O
ChoE(12:0)]. O

Previous O
study O
reported O
the O
up-regulation O
of O
bile O
acid O
of O
GCDCA O
(or O
GDCA), O
GCA, O
TCA, O
CDCA O
and O
down-regulation O
of O
LPC B-lipid
(18:0), I-lipid
LPC B-lipid
(18:1), I-lipid
LPC B-lipid
(16:0) I-lipid
in O
serum O
of O
patients O
with O
hepatitis O
B O
versus O
healthy O
controls. O

When O
the O
severe O
group O
only O
was O
considered, O
two O
lipid O
metabolites O
(TAG(42:2) O
and O
TAG(42:1)), B-lipid
were O
positively O
correlated O
with O
parasitaemia O
and O
16 O
exhibited O
a O
negative O
correlation. O

Significant O
metabolites O
according O
to O
the O
jack-knife O
confidence O
intervals O
were: O
oleic O
acid O
(lower O
levels O
in O
pre-symptomatic O
individuals O
compared O
with O
controls), O
as O
well O
as O
kynurenine O
and O
LPC(16:0) B-lipid
(higher O
levels O
in O
pre-symptomatic O
individuals O
in O
comparison O
to O
controls). O

Using O
a O
similar O
analytical O
technique, O
MALDI O
imaging O
mass O
spectrometry, O
Mirnezami O
et O
al. O
have O
reported O
elevated O
levels O
of O
PC B-lipid
16:0/18:1 I-lipid
in O
colon O
tumor O
samples; O
however, O
this O
particular O
PC O
was O
not O
among O
the O
most O
altered O
PL O
species O
in O
our O
samples. O

From O
our O
study, O
the O
observed O
progressive O
decrease O
in O
the O
concentration O
levels O
of O
AA, O
DHA, O
DPA, O
lysophospholipids O
and O
their O
downstream O
products O
such O
as O
eicosatrienoic B-lipid
acid I-lipid
after O
reperfusion O
strongly O
endorses O
the O
possible O
part O
that O
PLA_2 O
plays O
in O
disturbed O
phospholipid O
homeostasis O
during O
the O
transition O
from O
reversible O
to O
irreversible O
ischemic O
myocardial O
injury. O

As O
far O
as O
we O
know, O
no O
previous O
studies O
have O
focused O
on O
the O
role O
of O
LysoPC(22:6) B-lipid
on O
carotid O
plaque O
formation O
or O
stability O
but O
increased O
levels O
in O
symptomatic O
LAA O
patients O
could O
point O
to O
a O
role O
in O
this O
processes. O

It O
was O
found O
that O
short O
chain O
fatty O
acids O
(heptanoic O
acid, O
octanoic B-lipid
acid, I-lipid
nonanoic B-lipid
acid, I-lipid
hexanoic B-lipid
acid I-lipid
and O
capric O
acid) O
were O
up O
regulated, O
while O
glucose-6-phosphate O
was O
down O
regulated. O

Tandem O
mass O
spectrometry O
(MS/MS) O
experiments O
confirmed O
the O
assignment O
of O
m/z O
760.6 O
as O
phosphatidyl‐choline O
(PC) O
species O
16:0/18:1, O
m/z O
478.3 O
as O
LysoPC(16:0) B-lipid
and O
m/z O
504.3 O
as O
LysoPC(18:1). B-lipid

For O
example, O
recovery O
of O
PC(19:0/15:1) B-lipid
(p<0.001) O
increased O
by O
40%, O
and O
PE(20:3/18:1) B-lipid
(p=0.012) O
increased O
by O
58%. O

_– O
A O
double-blind O
randomized O
placebo-controlled O
study O
found O
that O
DHA O
or O
eicosapentaenoic B-lipid
acid I-lipid
added O
to O
ARA O
supplementation O
could O
reduce O
behavioural O
problems O
in O
children O
with O
autism. O

The O
decrease O
in O
the O
fatty O
acid O
is O
also O
reflected O
in O
the O
decrease O
of O
serum O
TAG(54:5) B-lipid
which O
might O
well O
be O
made O
up O
of O
2 O
16:0 O
(one O
of O
the O
most O
common O
fatty O
acids—Fig. O

ng/(0.4 O
μg O
extract), O
while O
PC B-lipid
18:1/16:0 I-lipid
was O
0.1 O
ng/(0.4 O

Hexadecanoic B-lipid
acid. I-lipid

Four O
amino O
acids O
were O
significantly O
affected O
by O
age O
(lysine, O
phenylalanie, O
valine O
and O
xleucine), O
14 O
metabolites O
by O
batch O
assignments O
(AC O
(2:0), O
AC O
(4:0-DC), O
AC O
(14:1), O
citrulline, O
glycine, O
methionine, O
ADMA, O
kynurenine, O
PC-O O
(31:1), O
PC-O O
(34:0), O
PC-O O
(36:2), O
SM B-lipid
(34:1), I-lipid
CE B-lipid
(18:1) I-lipid
and O
CE B-lipid
(18:2)), I-lipid
and O
four O
metabolites O
(glycine, O
ADMA, O
PC-O O
(34:0) O
and O
hexose) O
were O
elevated O
in O
SPMS O
patients O
compared O
to O
controls O
(Fig. O

In O
this O
study, O
the O
levels O
of O
α-linolenic O
acid O
(C18:3) O
and O
its O
downstream O
ω-3 O
PUFA O
metabolites, O
including O
eicosapentaenoic B-lipid
acid I-lipid
(C20:5), O
docosapentaenoic B-lipid
acid I-lipid
(C22:5), O
and O
docosahexaenoic B-lipid
acid I-lipid
(C22:6), O
were O
lower O
in O
the O
LC O
group O
than O
the O
control O
group; O
however, O
docosapentaenoic B-lipid
acid I-lipid
(C22:5) O
and O
docosahexaenoic B-lipid
acid I-lipid
(C22:6) O
did O
not O
show O
significant O
differences. O

LPA(17:0) B-lipid
was O
used O
as O
an O
internal O
standard. O

Analyses O
were O
conducted O
in O
148 O
participants O
in O
the O
Cholesterol B-lipid
and O
Pharmacogenetics O
study O
who O
were O
profiled O
pre O
and O
six O
weeks O
post O
treatment O
with O
40 O
mg/day O
simvastatin: O
100 O
randomly O
selected O
from O
the O
full O
range O
of O
the O
LDL-C O
response O
distribution O
and O
24 O
each O
from O
the O
top O
and O
bottom O
10% O
of O
this O
distribution O
(“good” O
and O
“poor” O
responders, O
respectively). O

The O
branching O
ratio O
is O
the O
ratio O
of O
peak O
areas O
of O
two O
mass O
transitions O
of O
Cer(22:0) B-lipid
(m/z O
622 O
to O
264 O
/ O
m/z O
622 O
to O
280) O
or O
Cer(24:0) B-lipid
(m/z O
650 O
to O
264 O
/ O
m/z O
650 O
to O
280), O
used O
to O
assure O
specificity O
of O
the O
detection. O

The O
absolute O
concentrations O
(ng/ml) O
of O
each O
PC O
and O
PE O
were O
calculated O
based O
on O
the O
peak O
areas O
of O
the O
PC O
and O
PE O
identified O
in O
the O
sample O
and O
the O
peak O
areas O
of O
the O
internal O
standards O
of O
PC(15:0/18:1) B-lipid
and O
PE(15:0/18:1) B-lipid
corresponding O
to O
the O
sample. O

The O
~2.5 O
fold O
higher O
concentration O
of O
Cer(24:0) B-lipid
compared O
to O
the O
Cer(22:0) B-lipid
in O
plasma O
was O
noted O
and O
also O
reported O
by O
another O
group. O

For O
endogenous O
lipid O
mediator O
analysis, O
blinded O
snap O
frozen O
serum O
and O
CSF O
samples O
were O
rapidly O
thawed O
and O
immediately O
combined O
with O
two O
volumes O
of O
cold O
methanol O
(4°C) O
containing O
deuterated O
internal O
standards O
prostaglandin O
E_2 O
(PGE_2 O
-d_4 O
), O
15(S)-hydroxyeicosatetraenoic B-lipid
acid I-lipid
(15(S O
)-HETE-d_8 O
) O
and O
(leukotriene O
B_4 O
LTB_4- O
d_4 O
), O
arachidonic O
acid O
(AA-d8) O
and O
docosahexaenoic B-lipid
acid I-lipid
(DHA-d5) O
(400 O
pg/each) O
to O
calculate O
the O
recovery O
of O
different O
classes O
of O
oxygenated O
polyunsaturated O
fatty O
acids O
and O
their O
substrates O
(AA, O
DHA). O

, O
PC B-lipid
(40:2) I-lipid
is O
lower O
in O
NRP O
compared O
with O
RP O
before O
and O
during O
treatment, O
probably O
resulting O
from O
dysregulation O
of O
choline O
metabolism, O
a O
known O
metabolic O
hallmark O
associated O
with O
oncogenesis O
and O
cancer O
progression. O

The O
urinary O
excretion O
of O
20-HETE B-lipid
was O
reduced O
in O
patients O
with O
RVD O
whether O
expressed O
as O
micrograms O
per O
hour O
or O
when O
factored O
for O
urinary O
excretion O
of O
creatinine. O

Before O
analysis, O
lipids O
were O
extracted O
from O
plasma O
(10 O
µl) O
with O
chloroform/methanol O
(2:1; O
20 O
vol) O
following O
the O
addition O
of O
internal O
standards: O
100 O
pmol O
each O
of O
ceramide O
17:0 O
(Matreya O
Inc., O
Pleasant O
Gap, O
PA), O
PC B-lipid
(13:0/13:0) I-lipid
and O
lysophosphatidylcholine O
(LPC) O
13:0; O
1000 O
pmol O
each O
of O
free O
cholesterol O
(Avanti O
Polar O
Lipids, O
Alabaster, O
AL) O
and O
cholesterol O
ester O
18:0- O
(CDN O
Isotopes, O
Pointe-Claire, O
Quebec, O
Canada); O
and O
100 O
pmol O
triglyceride O
(TG) O
17:0/17:0/17:0 O
and O
200 O
pmol O
diacylglycerol O
(DAG) O
15:0/15:0 O

Based O
on O
the O
constructed O
ROC O
curves, O
the O
AUC O
values O
of O
MG B-lipid
(18:2), I-lipid
GNOE, O
PE B-lipid
(18:2) I-lipid
and O
ZS O
were O
calculated O
to O
be O
0.828, O
0.772, O
0.798 O
and O
0.900, O
respectively, O
for O
BAV O
prediction. O

CHB-related O
alteration O
included O
palmitic O
acid, O
stearic O
acid, O
oleic O
acid, O
benzoic O
acid, O
butanoic B-lipid
acid, I-lipid
cholesterol, O
glycine, O
3-heptanone, O
4-heptanone, O
hexanal, B-lipid
1-tetradecanol O
and O
naphthalene O
metabolites. O

In O
addition, O
40% O
(2/5) O
of O
the O
unsaturated O
fatty O
acids O
(bishomo-gamma-linolenic O
acid O
and O
docosahexaenoic B-lipid
acid I-lipid
(DHA)) O
were O
increased, O
but O
others O
including O
11,14,17-eicosatrienoic B-lipid
acid, I-lipid
arachidonic O
acid, O
and O
eicosapentaenoic B-lipid
acid I-lipid
(EPA) O
were O
decreased. O

Nonpolar O
lipid O
metabolites O
were O
extracted O
from O
20 O
μL O
of O
serum O
in O
3 O
ml O
of O
2:1 O
chloroform:methanol O
and O
1 O
ml O
of O
PBS O
with O
inclusion O
of O
internal O
standards O
dodecylglycerol O
(10 O
nmol) O
and O
pentadecanoic B-lipid
acid I-lipid
(10 O
nmol). O

Other O
molecular O
ions O
identified O
in O
normal O
skin O
regions O
included O
palmitic O
(FA O
16:0) O
and O
palmitoleic O
(FA O
16:1) O
acids O
at O
m O
/z O
255.3 O
and O
253.2 O
(SI O
Appendix O
, O
Fig. O
S3F O
), O
respectively; O
glycerophosphoinositols O
38:4, O
PI B-lipid
(18:0/20:4), I-lipid
36:2, O
PI B-lipid
(18:2/18:0), I-lipid
and O
34:1, O
PI B-lipid
(16:1/18:0) I-lipid
at O
m O
/z O
885.6, O
861.6, O
and O
835.6, O
respectively; O
and O
glycerophosphoserine O
36:1, O
PS B-lipid
(18:1/18:0) I-lipid
at O
m O
/z O
788.5 O
(SI O
Appendix O
, O
Fig. O

(B) O
Representation O
of O
the O
molecular O
structure O
(C_24 O
H_48 O
NO_6 O
P) O
m/z O
478 O
identified O
as O
lisophosphatidylcholine O
[LPC O
(P-16:1)]. O

Three O
sphingolipids, O
Cer(d18:1/23:0), B-lipid
SM(d18:1/14:0), B-lipid
SM(d18:2/14:0) B-lipid
were O
decreased O
in O
EOC O
recurrent O
patients. O

Alternatively, O
Willenberg O
et O
al O
. O
mentioned O
product O
ion O
spectra O
of O
9-HETE B-lipid
and O
12-HETE B-lipid
were O
similar O
and O
these O
two O
compounds O
must O
be O
separated O
chromatographically O
for O
their O
identification. O

We O
examined O
the O
presence O
of O
mRNAs O
encoding O
4 O
human O
CYP450 O
isoforms O
that O
mediate O
20-HETE B-lipid
production: O
CYP4A11, O
CYP4A22, O
CYP4F2 O
and O
CYP4F3 O
in O
eight O
different O
human O
cancer O
tissue O
samples O
(breast, O
colon, O
kidney, O
liver, O
lung, O
ovary, O
prostate O
and O
thyroid). O

Then, O
1 O
mL O
methanol O
(-20°C) O
was O
used O
for O
extraction, O
following O
addition O
of O
30 O
μL O
2-chloro-L-phenylalanine O
(0.2 O
mg/mL) O
and O
60 O
μL O
heptadecanoic B-lipid
acid I-lipid
(0.05 O
mg/mL) O
as O
internal O
standards. O

, O
For O
instance, O
the O
sn O
-purity O
of O
the O
PC B-lipid
16:0/18:1 I-lipid
sample O
is O
93 O
± O
2%, O
meaning O
that O
it O
contains O
7 O
± O
2% O
PC B-lipid
18:1/16:0. I-lipid

Of O
these O
named O
metabolites O
included O
2-hydroxybutanoic B-lipid
acid, I-lipid
glucopyranose, O
citric O
acid, O
erythritol O
and O
ribitol. O
_1 O
H-NMR O
metabolite O
data O
was O
able O
to O
identify O
three O
significant O
metabolites O
across O
the O
designated O
time O
points O
of O
sample O
collection. O

In O
contrast O
with O
the O
LG O
BC O
group, O
the O
level O
of O
AIR, O
hypoxanthine, O
inosine, O
AFMK, O
indoleacetic O
acid, O
glycocholic O
acid, O
PS(O-18:0/0:0), B-lipid
phytosphingosine, O
sphinganine, O
linolenyl O
carnitine O
and O
LysoPC(20:0) B-lipid
were O
increased O
in O
the O
HG O
BC O
group, O
whereas O
the O
levels O
of O
3-hydroxydecanoyl O
carnitine O
and O
3-hydroxyoctanoyl O
carnitine O
were O
markedly O
decreased. O

For O
quantitation O
of O
fatty O
acids, O
calibration O
curves O
were O
prepared O
with O
heptadecanoic B-lipid
acid I-lipid
as O
internal O
standard O
(see O
above) O
and O
a O
fatty O
acid O
concentration O
range O
of O
0–1,000 O
μmol/ O

To O
evaluate O
the O
recoveries O
of O
the O
Cer(22:0) B-lipid
and O
Cer(24:0) B-lipid
from O
human O
plasma O
and O
matrix O
(5% O
BSA), O
signals O
of O
[_2 O
H_4 O
]Cer(22:0) O
and O
[_2 O
H_4 O
]Cer(24:0)from O
pre-extraction O
spiked O
samples O
to O
those O
post-extraction O
spiked O
samples O
were O
compared. O

All O
these O
results O
could O
pinpoint O
a O
beneficial O
effect O
of O
reduced O
LysoPC(16:0) B-lipid
levels O
that O
argue O
against O
our O
claim O
that O
it O
marks O
an O
early O
SR O
risk, O
but O
although O
high O
levels O
of O
plaque O
LysoPC(16:0) B-lipid
are O
correlated O
with O
high O
plasma O
and O
plaque O
levels O
of O
Lp-PLA2, O
plasma O
LysoPC(16:0) B-lipid
levels O
are O
not. O

Patients O
with O
FESZ O
had O
increased O
levels O
of O
creatine, O
and O
decreased O
levels O
of O
betaine, O
nonanoic B-lipid
acid, I-lipid
benzoic O
acid O
and O
perillic O
acid. O

Hexadecanedioic B-lipid
acid I-lipid
is O
a O
long-chain O
dicarboxylic O
acid, O
generated O
from O
fatty O
acid O
ω-oxidation O
and O
thereafter O
metabolized O
by O
β-oxidation O
in O
peroxisomes. O

For O
other O
PCs O
such O
as O
PC36:5 B-lipid
we O
found O
a O
V-pattern O
or O
a O
steady O
increase O
(PC40:7), O
both O
metabolites O
have O
been O
shown O
to O
be O
inversely O
associated O
with O
coronary O
artery O
disease O
and O
mortality. O

In O
another O
study, O
it O
was O
revealed O
that O
while O
intracellular O
concentrations O
of O
LTB4 B-lipid
can O
be O
higher O
in O
B-CLL O
cells O
relative O
to O
their O
normal O
counterpart, O
plasma O
concentrations O
of O
LTB4 B-lipid
may O
not O
be O
statistically O
different O
between O
patients O
and O
controls, O
the O
reason O
being O
that O
LTB4 B-lipid
can O
be O
metabolised O
into O
20-OH-LTB4 O
that O
is O
a O
non-circulating O
metabolite. O

Previous O
lipidomics O
analyses O
(not O
in O
bvFTD) O
showed O
that O
a O
considerable O
number O
of O
TG O
and O
DG O
species O
were O
closely O
associated O
with O
dyslipidemia, O
and O
TG B-lipid
50:2, I-lipid
52:2, O
52:3, O
and O
52:4 O
were O
the O
most O
abundant O
species. O

Moreover, O
because O
PC B-lipid
16:0_17:0 I-lipid
is O
a O
saturated O
lipid, O
it O
cannot O
be O
analyzed O
for O
CC O
location O
isomers. O

Our O
study O
found O
that O
esters O
of O
short O
chain O
fatty O
acids, O
cyclohexanecarboxylic O
acid O
and O
its O
derivatives O
were O
present O
in O
increased O
abundance O
in O
the O
feces O
of O
IBS-D O
patients O
compared O
with O
active O
IBD, O
while O
fecal O
aldehydes, O
such O
as O
heptanal B-lipid
and O
propanal, B-lipid
were O
more O
abundant O
in O
active O
CD O
(p<0.05). O

Histograms O
presented O
in O
Figure O
indicated O
that O
Acetylcarnitine O
had O
significant O
alterations O
in O
any O
two O
groups, O
while O
PC B-lipid
(42:11) I-lipid
and O
LPE(22:0/0:0) B-lipid
were O
significantly O
altered O
in O
short-term O
mortality O
and O
medium O
survival. O

The O
CV O
of O
each O
metabolite O
was O
as O
follows: O
tetradecane O
(−1.14783E-05), O
alpha-D-glucopyranoside O
(−4.47826E-06), O
methyl O
stearate O
(−6.08696E-06), O
dodecane O
(−7.6087E-06), O
1-4-benzene O
(1.44348E-05), O
D-galactose O
(−2.6087E-06) O
and O
octadecanoic B-lipid
acid I-lipid
(1.02609E-05). O

Since O
CYP4F2 O
is O
the O
major O
enzyme O
involved O
in O
the O
production O
of O
20-HETE B-lipid
in O
man O
and O
antibodies O
are O
available O
for O
this O
specific O
isoform, O
we O
further O
investigated O
whether O
the O
expression O
of O
CYP4F2 O
is O
also O
elevated O
at O
the O
protein O
level O
in O
ovarian O
cancer. O

and O
Cer(24:0) B-lipid
and O
their O
deuterated O
internal O
standards O
were O
extracted O
by O
protein O
precipitation O
and O
chromatographically O
separated O
by O
HPLC. O

ROC O
curves O
for O
combination O
of O
4-hydroxypentenoic B-lipid
acid, I-lipid
arabinose, O
glycochenodeoxycholate-3-sulfate, O
isoleucine, O
serine, O
and O
xanthine. O

With O
regard O
to O
other O
fatty O
acids, O
we O
found O
depressed O
heart O
failure O
patients O
had O
lower O
concentrations O
of O
fatty O
acids O
such O
as O
docosahexaenoic B-lipid
acid I-lipid
(DHA) O
compared O
with O
non-depressed O
patients O
but O
the O
differences O
were O
not O
different O
statistically. O

After O
the O
3-year O
follow-up, O
the O
control O
group O
showed O
significant O
decreases O
in O
the O
following O
12 O
metabolites: O
lysophosphatidylcholines O
(lysoPCs) O
containing O
C14:0, O
C16:1, O
C16:0, O
C17:0, O
C18:1, O
C18:0, O
C20:4, O
C20:3, O
and O
C22:6 O
(Suppl. O
1), O
PC B-lipid
(16:0/18:1), I-lipid
PC B-lipid
(18:0/18:2), I-lipid
and O
PC B-lipid
(18:0/20:4). I-lipid

For O
CYP450 O
related O
compounds O
of O
the O
AA-pathway, O
14,15-DiHETrE B-lipid
and O
11,12-DiHETrE B-lipid
were O
found O
to O
be O
present O
at O
higher O
levels O
than O
8,9-DiHETrE B-lipid
and O
5,6-DiHETrE. B-lipid
Epoxides O
of O
the O
AA-pathway O
were O
below O
the O
detection O
limit O
and O
thus O
not O
detected O
in O
these O
samples. O

For O
the O
Folch O
method, O
the O
1:10, O
1:20, O
and O
1:100 O
(v/v) O
sample-to-solvent O
ratios O
provided O
higher O
peak O
areas O
for O
Cer(d18:1/22:0) B-lipid
and O
many O
LPC/PC O
lipid O
classes O
compared O
to O
the O
1:4 O
(v/v) O
sample-to-solvent O
ratio. O

The O
variations O
of O
three O
metabolites O
(lysoPC(16:1), O
octanoylcarnitine O
and O
decanoylcarnitine) O
before, O
during, O
and O
after O
CRT O
treatment O
are O
suggestive O
of O
partial O
normalization O
in O
β-oxidation, O
glycolysis O
and O
energy O
metabolism O
in O
ESCC O
patients O
as O
a O
result O
of O
treatment. O

The O
inter-run O
precision O
was O
in O
the O
range O
of O
3.2%CV O
and O
3.6%CV O
for O
Cer(22:0) B-lipid
and O
Cer(24:0), B-lipid
respectively. O

While O
no O
significant O
change O
was O
observed O
at O
60 O
and O
100 O
°C O
during O
three O
heating O
periods, O
most O
of O
glutamate O
and O
PC B-lipid
(16:0/0:0) I-lipid
were O
absent O
after O
heating O
at O
250 O
°C O
for O
300 O
s. O
Glutamate O
seems O
to O
be O
among O
the O
most O
labile O
compounds. O

Finally, O
an O
analysis O
of O
the O
postprandial O
behavior O
of O
candidate O
FIBs, O
in O
particular O
the O
dairy O
fatty O
acids O
pentadecanoic O
acid O
and O
heptadecanoic B-lipid
acid, I-lipid
revealed O
specific O
kinetic O
patterns O
of O
relevance O
to O
their O
detection O
in O
future O
validation O
studies. O

We O
are O
also O
able O
to O
detect O
4-hydroxy-2-nonenoic B-lipid
acid I-lipid
(HNA)-MA, O
4-hydroxy-2-nonenoic O
acid O
lactone O
(HNAL)-MA, O
and O
4-oxo-2-nonenoic B-lipid
acid I-lipid
(ONA)-MA O
with O
this O
method. O

Representative O
chromatogram O
of O
m/z O
522.3451 O
in O
a O
biological O
sample O
(A) O
and O
PC B-lipid
(18:1) I-lipid
standard O
(B) O
at O
11.75 min. O

What’s O
more, O
some O
studies O
have O
reported O
that O
changed O
concentrations O
of O
lysoPCs O
are O
associated O
with O
the O
risk O
of O
T2DM, O
especially O
lysoPC(18:2), B-lipid
which O
was O
significantly O
altered O
in O
patients O
with O
impaired O
glucose O
tolerance O
(IGT) O
and O
was O
identified O
as O
an O
IGT-specific O
biomarker. O

Butanoic B-lipid
acid I-lipid
was O
increased O
in O
responders O
(FC: O
2.30, O
p O
= O
0.041), O
which O
is O
a O
direct O
agonist O
of O
the O
G-protein O
coupled O
receptor O
(GPCR), O
hydroxycarboxylic O
acid O
receptor O
2 O
(HCA_2 O
) O
to O
induce O
vasodilation O
and O
inhibit O
atherosclerotic O
activity. O

To O
date, O
decanoic B-lipid
acid I-lipid
has O
not O
been O
reported O
to O
be O
a O
biomarker O
of O
cancer. O

From O
neutrophil O
action, O
and O
with O
the O
participation O
of O
ω-hydroxylase, O
LTB4 B-lipid
is O
oxidized O
to O
20-carboxy O
LTB4. O

Twenty-one O
of O
the O
67 O
metabolites O
between O
healthy O
and O
hepatic O
were O
unique, O
including O
2-hydroxybutanoic B-lipid
acid, I-lipid
2-ketoisocaproic O
acid, O
α-ketoglutarate, O
glycerol-alpha-phosphate, O
oxamic O
acid, O
urea, O
and O
uridine. O

Heimerl O
et O
al. O
detected O
significant O
negative O
correlations O
between O
BMI O
and O
the O
levels O
of O
unsaturated O
LPC, O
LPC15:0, B-lipid
LPC18:1, B-lipid
LPC18:2, B-lipid
LPC18:3, B-lipid
LPC20:0, B-lipid
and O
LPC22:6. B-lipid

Both O
the O
lipids, O
PC B-lipid
(39:6) I-lipid
and O
FA B-lipid
(22:3) I-lipid
could O
influence O
the O
cataloging O
of O
patients O
with O
100% O
sensitivity O
(all O
18 O
control O
samples O
are O
classified O
correctly) O
and O
77.7% O
specificity O
(of O
18 O
tumor O
samples O
4 O
samples O
are O
misclassified) O
with O
p O
-value O
of O
1.612×10_−6 O
in O
Fischer’s O
exact O
test. O

The O
instrument O
was O
tuned O
by O
direct O
infusion O
of O
PG B-lipid
(17:0/17:0) I-lipid
in O
both O
positive O
and O
negative O
mode O
and O
external O
mass O
calibration O
was O
performed O
using O
the O
standard O
calibration O
mixture O
and O
protocol O
from O
Thermo O
Fisher O
approximately O
every O
five O
days. O

A O
three O
lipid O
signature O
including O
ePC O
38:5, O
PC B-lipid
40:3 I-lipid
and O
PC B-lipid
42:4 I-lipid
is O
potential O
to O
screen O
patients O
for O
diagnosis O
of O
PCa. O

The O
abbreviations O
listed O
here O
refer O
to O
the O
lipid O
classes O
and O
subclasses, O
the O
number O
of O
carbons O
and O
double O
bonds O
will O
be O
listed O
when O
referring O
to O
individual O
lipid O
species, O
such O
as O
LPC(22:6) B-lipid
which O
defines O
a O
lysophosphatidylcholine O
containing O
a O
fatty O
acid O
comprising O
22 O
carbon O
atoms O
and O
six O
double O
bonds. O

None O
of O
the O
analyzed O
samples O
contained O
signals O
representing O
a O
relevant O
interference O
with O
the O
selected O
internal O
standards O
(IS) O
DG O
40:0, O
TG B-lipid
51:0, I-lipid
and O
TG B-lipid
57:0 I-lipid
(ESM O
Fig. O

However, O
the O
reason O
why O
LacCer B-lipid
(d18:1/16:0) I-lipid
level O
does O
not O
increase O
in O
patients O
with O
recurrence O
remains O
to O
be O
elucidated. O

Although O
most O
patients O
with O
FESZ O
received O
medication O
and O
should O
be O
carefully O
considered, O
two O
independent O
sample O
sets O
were O
analyzed O
and O
increased O
levels O
of O
creatine, O
and O
decreased O
levels O
of O
betaine, O
nonanoic B-lipid
acid, I-lipid
benzoic O
acid O
and O
perillic O
acid O
were O
identified O
in O
patients O
with O
FESZ. O

The O
upregulation O
of O
SM(d18:0/24:1) B-lipid
by O
oral O
high O
fat O
supplementation O
might O
have O
contributed O
to O
the O
overall O
health O
benefits O
of O
the O
HFS O
in O
postoperative O
pancreatic O
cancer O
patients, O
but O
further O
studies O
are O
warranted O
to O
confirm O
this O
finding. O

Drift O
of O
retention O
time O
of O
each O
peak O
was O
minimized O
by O
locking O
heptadecanoic B-lipid
acid I-lipid
at O
36.00 min O
with O
retention O
time O
locking O
technology O
(RTL, O
Agilent). O

JWH-073 O
hydroxyindole, O
JWH-200 O
5-hydroxyindole, O
and O
JWH-210 O
pentanoic B-lipid
acid I-lipid
were O
not O
detected, O
even O
when O
samples O
contained O
other O
metabolites O
originating O
from O
the O
same O
parent O
compound. O

Extraction O
of O
precursors O
of O
m/z O
279.233±10 O
ppm O
from O
the O
negative O
ion O
CTS O
data O
revealed O
phospholipids O
containing O
linoleic O
acid O
including O
the O
[M−15]_− O
and O
[M+OAc]_− O
of O
PC(16:0 O
/18:2) O
at O
m/z O
742 O
and O
816, O
[M−15]_− O
and O
[M+OAc]_− O
of O
PC(18:0/18:2) B-lipid
at O
m/z O
770 O
and O
844, O
and O
the O
[M−H]_− O
of O
PI(18:0/18:2) B-lipid
at O
m/z O
861 O
(. O

We O
found O
that O
three O
serum O
metabolites O
(3,4-dihydroxybutanoic O
acid, I-lipid
docosapentaenoic B-lipid
acid, I-lipid
uric O
acid) O
jointly O
contributed O
to O
the O
separation O
between O
demented O
patients O
and O
controls O
and O
to O
the O
prediction O
of O
conversion O
to O
dementia. O

Internal O
standard O
(ISTD) O
compounds: O
creatinine-d_3 O
(hydrophilic) O
was O
purchased O
from O
CDN O
Isotopes O
(Pointe-Claire, O
Canada); O
lysine-d_4 O
(hydrophilic) O
and O
testosterone-d_2 O
(hydrophobic) O
were O
purchased O
from O
Cambridge O
Isotope O
Laboratories O
(Andover, O
Massachusetts); O
heptadecanoic B-lipid
acid I-lipid
(17:0 O
FA) O
and O
cis O
-10-nonadecenoic O
acid O
(19:1 O
FA) O
were O
purchased O
from O
Sigma-Aldrich O
(St. O
Louis, O
Missouri). O

A O
net O
reclassification O
index O
(NRI) O
analysis O
demonstrated O
that O
the O
addition O
of O
SM B-lipid
d16:1/18:0 I-lipid
and O
SM B-lipid
d18:1/18:0 I-lipid
to O
the O
current O
clinical O
standard O
of O
HbA1c O
or O
HbA1c O
plus O
BMI O
provides O
moderately O
improved O
accuracy O
of O
the O
prediction O
of O
diabetes O
incidence O
for O
38%–40% O
of O
individuals. O

Three O
epoxyeicosatrienoic O
acids O
(EETs), O
which O
are O
P450 O
metabolites O
of O
AA, O
and O
included O
11,12-EET, B-lipid
14,15-EET, B-lipid
and O
5,6-EET B-lipid
were O
also O
present O
in O
higher O
level O
in O
young O
women. O

In O
the O
H O
group, O
Firmicutes O
(Bacillus, O
Solibacillus O
and O
Lactococcus O
) O
were O
grouped O
with O
sugars O
(d-galactose, O
sedoheptulose), O
sugar O
alcohols, O
and O
organic O
acids, O
such O
as O
nonanoic B-lipid
acid, I-lipid
benzoic O
acid O
and O
others O
(hexane, O
1-acetyl-2-methyl-azetidine). O

The O
1.22 O
± O
0.09 O
mmol/l O
(173 O
± O
6.09%) O
increase O
in O
total O
PC O
after O
the O
rHDL O
infusion O
could O
be O
attributed O
to O
the O
34:3, O
34:2, O
36:3, O
and O
36:2 O
species; O
however, O
the O
expected O
increase O
in O
PC B-lipid
36:4 I-lipid
was O
not O
observed. O

As O
previous O
studies O
have O
shown O
that O
lipid O
ratios O
can O
be O
predictive O
of O
certain O
diseases, O
we O
noted O
that O
when O
the O
raw O
intensity O
value O
of O
PS(18:0_20:4) B-lipid
was O
divided O
by O
the O
sum O
of O
the O
raw O
intensity O
values O
of O
these O
three O
PS O
lipids, O
all O
fatal O
outcomes O
had O
a O
value O
of O
less O
than O
28.5 O
(average O
value O
of O
21) O
( O
and O
SI O
Appendix O
, O
Fig. O

Plasma O
20-HETE B-lipid
significantly O
correlated O
with O
plasma O
renin O
activity O
in O
renovascular O
disease O
(r O
_s O
=0.67; O
n=10; O
P O
<0.05). O

12- O
hydroxyeicosatetraenoic O
acid O
(HETE), O
docosahexaenoic B-lipid
acid I-lipid
(DHA), O
arachidonic O
acid O
(AA), O
and O
prostaglandin O
(PG) O
derivatives O
were O
detected O
at O
relatively O
high O
levels O
among O
the O
monitored O
ions. O

These O
metabolites O
included O
N-succinyl-2,6-diaminopimelate, O
deoxycholic O
acid O
glycine O
conjugate, O
octanoylcarnitine, O
LPCs, O
LPE B-lipid
(20:2), I-lipid
PC B-lipid
(34:1), I-lipid
PSs, O
and O
cholesteryl O
acetate. O

Our O
data O
in O
centenarians O
support O
promotion O
of O
cellular O
detoxification O
mechanisms O
through O
specific O
modulation O
of O
the O
arachidonic O
acid O
metabolic O
cascade O
as O
we O
underpinned O
increased O
concentration O
of O
8,9-EpETrE, B-lipid
suggesting O
enhanced O
cytochrome O
P450 O
(CYP) O
enzyme O
activity. O

